209 related articles for article (PubMed ID: 3014339)
1. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
Fromtling RA; Abruzzo GK; Bulmer GS
Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
[TBL] [Abstract][Full Text] [Related]
2. [In vitro susceptibility of Cryptococcus strains to 5 antifungal drugs].
Bava AJ; Negroni R
Rev Inst Med Trop Sao Paulo; 1989; 31(5):346-50. PubMed ID: 2560840
[TBL] [Abstract][Full Text] [Related]
3. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
Del Poeta M; Barchiesi F; Morbiducci V; Arzeni D; Marinucci G; Ancarani F; Scalise G
J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
Poon M; Cronin DC; Wormser GP; Bottone EJ
Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts.
Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G
Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421
[TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
Thompson GR; Wiederhold NP; Fothergill AW; Vallor AC; Wickes BL; Patterson TF
Antimicrob Agents Chemother; 2009 Jan; 53(1):309-11. PubMed ID: 18955539
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts.
Fromtling RA; Yu HP; Shadomy S
Mycopathologia; 1984 Apr; 86(1):45-50. PubMed ID: 6330557
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
Khan ZU; Randhawa HS; Kowshik T; Chowdhary A; Chandy R
J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
[TBL] [Abstract][Full Text] [Related]
11. The postantibiotic effect of antifungal agents against common pathogenic yeasts.
Turnidge JD; Gudmundsson S; Vogelman B; Craig WA
J Antimicrob Chemother; 1994 Jul; 34(1):83-92. PubMed ID: 7961219
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
14. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
15. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.
Doern GV; Tubert TA; Chapin K; Rinaldi MG
J Clin Microbiol; 1986 Oct; 24(4):507-11. PubMed ID: 3533974
[TBL] [Abstract][Full Text] [Related]
16. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.
Hoeprich PD; Merry JM
J Clin Microbiol; 1986 Aug; 24(2):269-71. PubMed ID: 3528213
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of Fungitest-, Neo-Sensitabs- and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans.
Swinne D; Raes-Wuytack C; Van Looveren K; Desmet P
Mycoses; 1999; 42(4):231-7. PubMed ID: 10424089
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of Cryptococcus neoformans serotypes to GM 237354 derivative of the sordarin class.
Torres-Rodríguez JM; Morera Y; Baró T; López O; Alía C; Jiménez T
Mycoses; 2002 Oct; 45(8):313-6. PubMed ID: 12572721
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
